Marion's Prothiaden
Executive Summary
Boots is reacquiring from Marion all U.S. rights to the tricyclic antidepressant (dothiepin HCl), which is not yet approved in the U.S. The agreement includes cash and other periodic payments based on Boots' sales. Boots markets the product in 14 countries; Marion, which obtained U.S. rights in the early 1970s, will continue all R&D under the existing NDA until FDA approval.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.